White House Schedules FDA Meetings on Cannabis Enforcement — What It Means for the Industry

The White House has scheduled four meetings this week with cannabis industry stakeholders to discuss FDA enforcement policy for CBD and hemp-derived products. The meetings, which include representatives from major operators like Jushi Holdings and Story Cannabis as well as hemp farmers, signal that the federal government is actively working toward a regulatory framework that has been years in the making.

This matters. A lot.

Why FDA Enforcement Policy Matters

Since the 2018 Farm Bill legalized hemp and its derivatives, the CBD market has operated in regulatory limbo. Hemp-derived CBD is technically legal, but the FDA has never established a clear regulatory pathway for CBD in food, beverages, or dietary supplements. The agency has sent warning letters to companies making unsubstantiated health claims, but it hasn't created the comprehensive framework the industry needs to operate with confidence.

The result has been a market where quality ranges wildly, consumer protections are inconsistent, and legitimate operators compete against products that may not contain what their labels claim. For consumers shopping for CBD products — including those browsing vendors on Hightree — the lack of federal standards means lab testing and brand reputation become the only reliable quality signals.

What's Being Discussed

The White House meetings are focused on enforcement policy specifically — not legalization or rescheduling, but how existing laws are applied to cannabis and hemp products in commerce. Key questions on the table likely include:

For CBD products:

• Will the FDA create a regulatory pathway for CBD in food and supplements?
• What enforcement actions will be taken against non-compliant products?
• How will interstate commerce in CBD products be regulated?

For hemp-derived THC:

• How will the FDA address hemp-derived Delta-8, Delta-9, and other psychoactive products that exist in a legal gray area under the Farm Bill?
• Will there be manufacturing and testing standards for hemp-derived cannabinoid products?

For the broader industry:

• How will FDA enforcement interact with state-level regulations?
• What role will the FDA play in product safety — testing requirements, labeling standards, dosing guidelines?

What This Could Mean

A clear FDA enforcement framework would be transformative for the cannabis industry. Here's what different outcomes could look like:

Best case: The FDA establishes a regulatory pathway for CBD in food and supplements, sets manufacturing standards, and creates clear labeling requirements. This legitimizes the market, drives out bad actors, and gives consumers confidence in what they're buying. Major retailers who've been waiting on FDA clarity could begin stocking CBD products at scale.

Moderate case: The FDA increases enforcement against egregious violators (false health claims, contaminated products) while continuing to delay comprehensive regulation. The market continues operating in uncertainty, but with better guardrails.

Worst case: Restrictive enforcement that treats CBD as an unapproved drug, limiting availability and driving products back underground. This is unlikely given the political dynamics but remains a theoretical risk.

The Stakeholder Mix Tells a Story

The guest list for these meetings is revealing. Jushi Holdings is a multi-state cannabis operator with both medical and recreational operations. Story Cannabis is an emerging brand. And hemp farmers represent the agricultural side of the equation.

This mix suggests the White House is hearing from across the supply chain — not just Big Cannabis and not just small farmers. The inclusion of hemp farmers is particularly notable, as any FDA enforcement policy will directly affect the hemp industry's ability to sell CBD and other cannabinoid products.

What to Watch

The outcome of these meetings likely won't produce immediate policy changes. Federal rulemaking is slow by design. But several indicators will signal the direction:

1. Public statements after the meetings — look for language about "regulatory pathway" vs. "enforcement action"
2. FDA follow-up actions — new guidance documents, proposed rules, or enforcement announcements
3. Congressional response — whether lawmakers push for legislation to speed up or shape FDA's approach
4. Industry reaction — how publicly traded cannabis companies and industry associations respond to whatever comes out of these meetings

For Hightree vendors and shoppers, the practical impact depends on what framework emerges. Clearer federal standards could mean more consistent product quality across the marketplace, standardized testing requirements, and potentially broader market access for hemp-derived products.

We'll be watching this closely and will report on developments as they emerge.

Source: Marijuana Moment